Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Treasury Shares (2016 - 2025)

Ultragenyx Pharmaceutical has reported Treasury Shares over the past 3 years, most recently at $8.0 million for Q4 2025.

  • Quarterly Treasury Shares rose 100.0% to $8.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.0 million through Dec 2025, up 100.0% year-over-year, with the annual reading at $8.0 million for FY2025, 100.0% up from the prior year.
  • Treasury Shares was $800000.0 for Q4 2025 at Ultragenyx Pharmaceutical, up from $173034.0 in the prior quarter.
  • Over five years, Treasury Shares peaked at $2.1 million in Q4 2022 and troughed at $7812.0 in Q1 2023.
  • The 5-year median for Treasury Shares is $131172.0 (2024), against an average of $486674.9.
  • Year-over-year, Treasury Shares soared 835.96% in 2024 and then skyrocketed 100.0% in 2025.
  • A 3-year view of Treasury Shares shows it stood at $432000.0 in 2023, then surged by 825.93% to $4.0 million in 2024, then skyrocketed by 100.0% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Treasury Shares are $8.0 million (Q4 2025), $8.0 million (Q3 2025), and $8.0 million (Q2 2025).